Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases
Hematological Oncology · 2026-11 · 44 (6)
DOI: 10.1002/hon.70283 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hematological Oncology, online erschienen am 05.11.2026. Verfasst von Peng Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Gene Rearrangement, Eosinophilia, Hematologic Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Health Subsidy Program of Hunan Provincial Department of Finance.
Abstract (Originalsprache)
MLN‐Eo (Myeloid/Lymphoid Neoplasms with Eosinophilia) harboring FLT3 rearrangement is an extremely rare hematologic malignancy for which standardized treatment guidelines are currently lacking. This systematic review synthesizes the largest cohort (39 cases) to date of FLT3‐ rearranged MLN‐Eo. The available evidence supports the role of hematopoietic stem cell transplantation (HSCT) as the cornerstone for achieving long‐term survival and as a potentially curative intervention under current treatment modalities. Tyrosine kinase inhibitors (TKIs) can be used as bridging therapy to transplantation by inducing remission and reducing tumor burden. For patients ineligible for HSCT, TKI‐based regimens (combined with chemotherapy) are recommended for disease control, while chemotherapy alone is strongly discouraged due to uniformly poor outcomes. These findings provide a practical treatment framework based on the currently available evidence and may help inform clinical decision‐making for this rare and challenging disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, Hunan, China.
- Hunan Hematology Oncology Clinical Medical Research Center, Changsha, Hunan, China.
- SANO Medical Laboratories, Suzhou Sano Precision Medicine Ltd, Suzhou, Jiangsu, China.
- Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, Jiangsu, China.
ORCID-Profile: Sheng Xiao, Lijun Meng, Yan Chen
Förderung
- Health Subsidy Program of Hunan Provincial Department of Finance
Zitieren
APA
Fang, P., Zhang, P., Yang, F., Yang, M., Xiao, S., Meng, L., & Chen, Y. (2026). Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70283
Vancouver
Fang P, Zhang P, Yang F, Yang M, Xiao S, Meng L, et al. Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70283
BibTeX
@article{Fang2026,
author = {Fang, Peng and Zhang, Peng and Yang, Fan and Yang, Mei and Xiao, Sheng and Meng, Lijun and Chen, Yan},
title = {Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {6},
doi = {10.1002/hon.70283}
}
EUVIMED